The RAS and BRAF mutation status was frequently unknown in this study, as it was not routinely performed as a standard of care for patients with metastatic CRC in the past and is still not routinely performed for patients who do not receive systemic therapy. This evidence concerns the gene BRAF and colorectal carcinoma.